Toho Holdings Co., Ltd.
Stock Price Chart
2026/03/02 UpdatedPrice Trend
2026/03/02 UpdatedPrice & Trading Details
2026/03/02 UpdatedPRICE
TRADING
Analyst Recommendations 3 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Dividend History 4Years Growth
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥85 | +80.9% |
| 2024 | ¥47 | +38.2% |
| 2023 | ¥34 | +9.7% |
| 2022 | ¥31 | +3.3% |
| 2021 | ¥30 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,266,171M | ¥1,392,117M | ¥1,476,712M | ¥1,518,495M |
| Gross Profit | ¥108,687M | ¥114,366M | ¥119,148M | ¥121,648M |
| Operating Income | ¥12,534M | ¥16,369M | ¥19,337M | ¥18,942M |
| Pretax Income | ¥20,186M | ¥20,492M | ¥30,845M | ¥28,102M |
| Net Income | ¥13,379M | ¥13,630M | ¥20,657M | ¥19,844M |
| EPS | ¥174.48 | ¥180.67 | ¥286.79 | ¥284.22 |
| Operating Margin | 0.99% | 1.18% | 1.31% | 1.25% |
| Balance Sheet | ||||
| Total Assets | ¥702,376M | ¥715,288M | ¥773,427M | ¥722,805M |
| Total Equity | ¥241,079M | ¥242,823M | ¥249,330M | ¥256,779M |
| Total Liabilities | ¥461,297M | ¥472,465M | ¥524,097M | ¥466,026M |
| Cash | ¥94,256M | ¥86,201M | ¥132,970M | ¥86,533M |
| Interest-bearing Debt | ¥40,737M | ¥37,888M | ¥30,244M | ¥21,260M |
| Equity Ratio | 34.32% | 33.95% | 32.24% | 35.53% |
| D/E Ratio | 0.17 | 0.16 | 0.12 | 0.08 |
| Cash Flow | ||||
| Operating CF | ¥16,341M | -¥9M | ¥59,934M | -¥26,675M |
| Investing CF | -¥11,032M | ¥4,315M | ¥9,091M | -¥4,180M |
| Financing CF | -¥4,473M | -¥13,060M | -¥22,195M | -¥20,364M |
| Free CF | ¥12,139M | -¥2,528M | ¥56,153M | -¥32,432M |
| Efficiency | ||||
| ROE | 5.55% | 5.61% | 8.29% | 7.73% |
| ROA | 1.90% | 1.91% | 2.67% | 2.75% |
Latest IR Information
-
Notice Regarding Request for Additional Information Provision Concerning Large-Scale Purchase of Our Shares
Toho Holdings requested additional information provision regarding the large-scale purchase of shares by 3D Investment Partners, judging that the information provided was insufficient for shareholder decision-making.
Read more -
Notice Regarding Revision of Dividend Forecast for the Fiscal Year Ending March 2026
Announced a revision to increase the year-end dividend forecast for the fiscal year ending March 2026 by 30 yen from 45 yen to 75 yen per share, raising the total annual dividend from 90 yen to 120 yen, up 55...
Read more -
FY2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)
For FY2026 Q3, net sales reached 1,183,158 million yen (1.8% YoY increase), operating income was 12,422 million yen (13.3% YoY decrease), and net income attributable to owners of parent for the quarter was 14,448 million yen (40.9% YoY increase).
Read more -
Notice of Receipt of Response to Request for Information Regarding Large-Scale Purchase and Other Actions Relating to Our Company’s Shares
On January 16, 2026, Toho Holdings Co., Ltd. requested information concerning a large-scale purchase by 3D Investment Partners Pte. Ltd., and received a response on February 3, 2026.
Read more -
Notice Regarding Request for Information Provision Concerning Large-Scale Purchase Activities of Our Company's Shares
Following the large-scale purchase activity of our shares by 3D Investment Partners Pte. Ltd., our company has requested the provision of necessary information from the party and initiated measures to provide shareholders with decision-making materials.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥4,933
Rating Score: 3.00 (Based on 3 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Toho Holdings Co., Ltd. engages in the wholesale distribution of pharmaceutical products in Japan. It operates in four segments: Pharmaceutical Wholesale Business, Dispensing Pharmacy Business, Pharmaceutical Manufacturing and Sales Business, and Other Peripheral Businesses. The company sells pharmaceuticals, narcotics, reagents, and medical devices to hospitals, clinics, and dispensing pharmacies. It is also involved in the management of the dispensing pharmacies business; operates health insurance pharmacy; provision of support home medical care services; peripheral businesses; core system operations; and real estate agency business. In addition, the company manufacture and sell pharmaceuticals; sells generic drugs; and manufactures injection drugs on consignment. Further, it provides support services, including the development and sale of customer support systems, assistance in the start-up of medical institutions and pharmacies, management consulting services, medical support, and personnel recruitment. Additionally, the company offers various customer support systems, including ENIF, an information terminal for pharmaceutical ordering; ENI-Pharmacy, a support system for the separation of dispensing and prescribing functions; LXMATE Helios a medical care appointment system; KAITOS, an online medical consultation and medication guidance system; ENIFwin Nex-Sus, an inventory control system for large hospitals ENIFvoice SP/ ENIFvoice SP + A/ ENIFvoice Core, a supporting system for electronic medication history recording with voice recognition. The company was incorporated in 1948 and is headquartered in Chuo, Japan.